What actually changed in 2026?
Two things made headlines, and they're different kinds of thing. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee, a panel of outside experts that advises the agency, voted to recommend six peptides for the list of ingredients licensed compounding pharmacies can use: BPC-157, KPV, TB-500, MOTS-c, Epithalon and Semax. BPC-157 and KPV each passed 8 to 6, with one abstention. A seventh, DSIP (listed as emideltide), failed by one vote. The panel went against the FDA's own scientists, who had advised against all seven, and our report on the vote has that side.
Then on October 14, a document called "Interim Access Policy for Compounding Using Certain Peptides" went to the White House Office of Management and Budget for review. It came out two weeks later from a slightly different place. On October 28, the Department of Health and Human Services (HHS) posted its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," signed by Secretary Robert F. Kennedy Jr., and the Federal Register published the notice on October 30 under the same tracking number. It names the same six peptides. Our news write-up on the published policy has the full story, and our October 27 snapshot shows what was known before it came out.
Why isn't a policy the same as legal?
Because three separate things all get called "legal," and the headlines blur them.
| What it is | Where it stands | |
|---|---|---|
| The law | The official 503A Bulks List | No peptide added yet |
| Advisory vote | Expert advice to the FDA | Six recommended in July |
| Enforcement policy | HHS says it won't act | Published October 28, a conditional draft |
The law is the federal compounding statute and its official list of allowed ingredients, called the 503A Bulks List. Adding a peptide to it takes formal rulemaking, with a proposal, public comment and a final rule, and that can take years. The advisory vote told the FDA what the panel thought, and the agency can accept it, change it or ignore it. An enforcement policy is the government telling pharmacies it won't take action against them for doing something the law doesn't allow yet. That's called enforcement discretion, and it's what HHS published in October.
What does the HHS policy do?
The notice says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with the six peptides, while the formal list is worked out through rulemaking. It calls the policy a draft, opens it to public comment, and says it "is not binding on HHS or the public." The full policy sits in a separate HHS document we couldn't open, so for the conditions we're relying on two legal readings, from Baker Hostetler and the FDA Law Blog. Per both, the compounder has to work from a valid prescription for an individual patient, make a single-ingredient product from raw peptide bought from an FDA-registered establishment, and report serious adverse events and quality problems to the FDA's MedWatch program, and the policy lists which forms are covered for each peptide.
What it leaves out matters as much. It doesn't approve any product or change the law, and Baker Hostetler says it doesn't cover the larger outsourcing facilities known as 503B, or products sold as research chemicals or dietary supplements. HHS keeps the right to revisit it "if, among other things, a safety signal or product quality issue arises," and the FDA Law Blog notes it's unclear whether state pharmacy boards will follow the federal lead. So the route is a prescription from a licensed prescriber, filled by a state-licensed compounding pharmacy willing to make it, within whatever your state allows. Our straight answer on getting BPC-157 from a pharmacy covers that route.
Who's pushing back?
On October 13, KFF Health News reported on people who say BPC-157 and other peptides left them with migraines, facial numbness and fatigue. The week after, the Regulatory Affairs Professionals Society, a regulatory trade group, reported that the Partnership for Safe Medicines had filed a citizen petition, a formal request to the FDA, arguing that compounding these peptides is illegal and unsafe. When the policy came out, Reuters quoted Robert Steinbrook of Public Citizen's Health Research Group saying Kennedy acted "recklessly and unilaterally," while the American Academy of Peptide Medicine called it a "landmark regulatory milestone." HHS says the aim is to expand patient access, and Kennedy has argued that a state-regulated pharmacy route gives people more protection than buying from unregulated sources. The public comment period is where both sides go next.
Does any of this change the research-use market?
Not directly. The vendors we compare sell vials labeled for research use only, which is a selling status rather than a legal permission, and our page on the research use only label explains it. The July vote and the HHS policy are both about the pharmacy route, and Baker Hostetler reads the policy as not covering products sold as research chemicals.
| Compounding pharmacy | Research-use vendor | |
|---|---|---|
| Needs | A prescription | Nothing |
| Touched by July vote | Yes, as advice | No |
| Touched by HHS policy | Yes, with conditions | Not on lawyers' reading |
| Quality check | Pharmacy rules and inspection | Vendor's batch testing |
The FDA is still watching how research peptides are sold. In August it sent warning letters to five online sellers, and our write-up on the research-use label failing five sellers covers what got them in trouble.
What should you watch for next?
The comment window runs about two weeks from the October 30 publication, into mid-November, and the notice says the HHS website will carry the current version, so the text can still change. After that, watch your state's pharmacy board, which can be stricter than the federal policy, and whether pharmacies near you start offering these. A second advisory committee meeting is due before the end of February 2027, with five more peptides, and our preview lists them. If you're asking about one compound, is BPC-157 legal has the short version.
What does it change when you shop?
After a favorable headline, some listings start using words like "approved," "cleared" or "now legal." The HHS policy is none of those, so a seller saying it is a reason to look harder at the seller, not a reason to relax. The things that matter are the same as last month: a batch-specific lab report, and our guide to reading a certificate of analysis (COA) shows what to look for, plus a vendor you can check. The vendor directory shows how each one is vetted, and the price comparison tool shows what they charge per milligram today. For the bigger picture of how approval works, see research peptides vs FDA-approved drugs.
This is reporting on public information as of October 31, 2026, not legal advice, and none of these compounds is FDA approved, so they're sold for research.
